A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience

Khosro Keshavarz, Amir Hashemi-Meshkini, Zahra Gharibnaseri, Shekoufeh Nikfar, Abbas Kebriaeezadeh, Mohammad Abdollahi

Abstract

Introduction: Fibromyalgia is a neuropathic syndrome which is more common in adult females. Pregabalin is the first medicine which was approved by the United States Food and Drug Administration for treatment of fibromyalgia. In this study we aimed to evaluate the cost-efficacy of pregabalin in the treatment of fibromyalgia in Iran.

Material and methods: To evaluate the efficacy of pregabalin, a systematic review was carried out by conducting a wide literature search for the main outcomes of interest that were pain score reduction from the baseline and the percentage of patients with more than 50% pain reduction. To evaluate costs of treatment, only the direct medical costs were considered. The calculated incremental cost-effectiveness ratio (ICER) were compared with one and three times the gross domestic product (GDP) per capita as the threshold to evaluate the economic condition of treatment to be “highly cost-effective”, “cost-effective” or “not cost-effective”.

Results: Out of 4012 searched reports, only four reports were included in the study, all of which were randomized controlled trials with placebo controls. The calculated ICERs for pregabalin 450 mg/day and 600 mg/day with both available forms of brand and generic medicines in the country were in the range of 44–1170 US dollars (USD) and 48–814 USD, which in all cases could be considered as highly cost-effective. Pregabalin 150 mg/day based on available evidence does not have significant efficacy in comparison to placebo. But for pregabalin 300 mg/day, no decision can be made based on current data.

Conclusions: Our analysis indicated that generic pregabalin in the treatment doses of 450 mg/day and 600 mg/day is highly cost-effective.

Key words: pregabalin, fibromyalgia, Lyrica, cost-effectiveness, systematic review, economic model, economic evaluation.

Introduction

Fibromyalgia is a worldwide chronic disease that is most common in adult females [1]. The prevalence of fibromyalgia in the United States (US) general population is about 2% [2] and in the UK is 2.8% [3]. Patients who...
suffer from fibromyalgia in Iran are estimated to constitute around 1.3% to 4% of the general population [4, 5]. Widespread pain for more than 3 months and tenderness in some selected tender points are the main signs of fibromyalgia based on criteria of the American College of Rheumatology 1990 for diagnosis of fibromyalgia [6]. Some medications have been used to manage fibromyalgia in Iran and other countries including pain control medication, antidepressants [7], and nutritional supplements [8], none of which is approved for this indication. Pregabalin is the first medicine that was approved by the US Food and Drug Administration (FDA) in 2007 for fibromyalgia [9]. Currently duloxetine and milnacipran are also approved by the FDA for fibromyalgia [10, 11]. The first one is available in Iran but in a very negligible volume and the second one is not available in the market because it has not been included in the Iranian Drug List (IDL).

The evidence indicates the considerable economic burden (2298 Canadian dollars only for direct medical costs) of fibromyalgia [12] both on patients and society [13], which has to be attended by policy makers in providing more cost-effective medicines and treatment strategy for the population. One of the important roles of government to implement the Iran national drug policy is to provide equal access for patients to essential drugs [14–16]. To put into operation this idea, affordability of medicines and balanced utilization of medicines should be achieved [17].

Pregabalin has recently become available in the Iranian market in both domestic generic and imported brand (Lyrica) forms. The price of pregabalin according to the Iranian drug basket could be considered high and is not currently covered by insurance. However, the results of economic evaluation for pregabalin in diabetic peripheral neuropathy in Iran showed that this drug is cost-effective in doses of 300 mg/day or 600 mg/day and they have been recommended to be added to the insurance coverage list [18] but cost-effectiveness of this drug for fibromyalgia has not been evaluated yet. Economic evaluation of medicines is a tool to assess national drug policy criteria such as accessibility and equity [15, 19].

Regarding the above statements, we aimed to analyze the cost-effectiveness of pregabalin in the treatment of fibromyalgia in comparison to other alternative treatments in Iran.

Material and methods

Data sources
To evaluate the efficacy of pregabalin in comparison to other alternatives, a systematic review of published studies was conducted. To cover all documents, databases of PubMed, Scopus, Google Scholar, and Cochrane were systematically searched using the keywords “fibromyalgia and pregabalin” and “fibromyalgia” from 1965 to 30 January of 2012. Published English language randomized controlled trial (RCT) studies which had pregabalin as one of their arms were included. Review articles, economic evaluation studies, studies on animals and observational studies were excluded. Full details of inclusion and exclusion criteria are presented in Table I. To evaluate cost of treatment with pregabalin, only the direct medical cost was considered in analysis, upon a clinical expert’s opinion. Given that there are no considerable laboratory monitoring and diagnostic tests or other supplementary treatment strategy, we only considered the cost of medicines in the analysis. The treatment’s cost was calculated based on the treatment period of included studies. The medical cost for both brand and generic products available in the Iranian market was calculated for every dose and each study. To calculate the cost of generic medicine we considered the cheapest combination of available dosage forms in Iran and for the brand ones we considered the most expensive combination. The exchange rate at the time declared by Iran’s central bank was used to exchange Iranian rials (IRR) to US dollars (USD).

Study selection
The title and abstracts of search results were reviewed separately by two authors to eliminate duplicate studies, unrelated subjects and other exclusion criteria. Then the selected articles were double checked before inclusion in the study. In the

Table I. Details of criteria in study selection

| Inclusion criteria | Exclusion criteria |
|--------------------|--------------------|
| – Published papers in English language | – Unpublished studies |
| – One arm of pregabalin | – Proceedings |
| – Controlled studies | – Biochemical, pharmacokinetic and non-clinical studies |
| – Subject of fibromyalgia | – Animal studies |
| | – Phase 1 and 2 clinical trials without pregabalin arm |
| | – Uncontrolled studies |
| | – Observational studies |
| | – Review studies |
| | – Economic evaluation studies |
next step, the full texts of selected studies were scrutinized and reviewed, which led to exclusion of some more studies.

**Quality assessment of included studies**

The methodological quality of each included study was assessed by the Jadad score, which gives every study a score between 0 and 5 based on descriptions of double-blindness, randomization and withdrawals [20]. Based on this method, studies with scores ≥ 3 were considered as high quality and studies with scores ≤ 2 were considered as low quality. In this study, a score less than 3 was considered as an exclusion criterion.

**Effects**

The outcome of interest for evaluation of efficacy was “pain score reduction from baseline”. The pain score was calculated from an 11-point scale (0 = no pain, 10 = worse possible pain) which was declared by the patients themselves for the last 24 h. Some RCTs reported another outcome, “percentage of patients with at least 50% reduction in pain”, which was included in our analysis as well.

**Incremental cost-effectiveness ratio**

Using the difference of cost and the difference in efficacy, the incremental cost-effectiveness ratio (ICER) for both brand and generic pregabalin in all treatment doses was calculated and parametric sensitivity analysis was performed using the confidence interval of efficacy in each study. The ICERs in this study were considered as the cost (USD) per one more score reduction in mean pain score in comparison to placebo or the cost (USD) needed to achieve one patient with more than 50% pain reduction. The ICERs were compared with both one and three times the gross domestic product (GDP) per capita upon recommendation of WHO-CHOICE [21] to evaluate whether the treatment of fibromyalgia with different evaluated doses is highly cost-effective (when the ICER was less than GDP per capita), cost-effective (when the ICER was between one and three times GDP per capita), or not cost-effective (when the ICER was more than three times GDP per capita), given that there is no accurate cost-effectiveness threshold (willingness to pay) calculated for health care technologies in Iran. The GDP per capita based on the latest statistics released (2010) was 5608 USD [22]. It is notable that the Iranian pharmaco- and health economists estimate the threshold for Iran to be approximately two times the threshold (10 000 USD).

**Results**

Out of 4012 articles from the searched databases, 3660 articles were from Google Scholar, 169 articles were from PubMed, and the rest were from Scopus. After reviewing the title and abstract, 6 articles were included in the study, and from these articles, two were excluded after reviewing the full text because they were not RCTs (Figure 1). Finally, 4 RCTs were included in our analysis [23–26]. For all included articles, the Jadad score was calculated, which is illustrated in Table II. The patients in these included studies were men and women more than 18 years old who had met American College of Rheumatology criteria for fibromyalgia diagnosis.

**Table II.** Jadad score to evaluate the quality of included studies

| Author, year [reference] | Randomization | Double-blind | Withdrawal and dropout | Total score |
|--------------------------|---------------|--------------|------------------------|-------------|
| Crofford et al., 2005 [25] | 2             | 1            | 1                      | 4           |
| Arnold et al., 2008 [24]  | 2             | 2            | 1                      | 5           |
| Mease et al., 2008 [23]   | 1             | 1            | 1                      | 3           |
| Paure et al., 2011 [26]   | 1             | 1            | 1                      | 3           |
Concerning pregabalin 450 mg/day, the calculated ICER for generic and brand pregabalin was in the range of 44–132 and 393–1170, respectively [23–26]. It showed that pregabalin 450 mg/day in both generic and brand forms could be considered as highly cost-effective treatment compared with placebo (Table IV). Also there was one study that reported the efficacy of pregabalin 450 mg/day according to the outcome of percentage of patients with more than 50% pain reduction [19] which resulted in the ICER of 771 and 6879 for its generic and brand forms, respectively (Table V). This means that both doses are highly cost-effective.

**Pregabalin 450 mg/day**

Concerning pregabalin 450 mg/day, the calculated ICER for generic and brand pregabalin was in the range of 44–132 and 393–1170, respectively [23–26]. It showed that pregabalin 450 mg/day in both generic and brand forms could be considered as highly cost-effective treatment compared with placebo (Table IV). Also there was one study that reported the efficacy of pregabalin 450 mg/day according to the outcome of percentage of patients with more than 50% pain reduction [19] which resulted in the ICER of 771 and 6879 for its generic and brand forms, respectively (Table V). This means that both doses are highly cost-effective.

**Pregabalin 600 mg/day**

Our analysis of pregabalin 600 mg/day showed that except one study that reported no significant efficacy [26], the range of ICER for generic and brand pregabalin 600 mg/day based on the other two studies [23, 24] is 48–115 and 340–814, respectively (Table IV). Also there was one study that

| Author, year [reference] | No. of patients | Age, mean ± SD (years) | Dosage | Concurrent therapy | Duration of study |
|--------------------------|-----------------|------------------------|--------|--------------------|------------------|
| Crofford et al., 2005 [25] | 45 484 | Placebo  Preg 150  Preg 300  Preg 450 | 150, 300 and 450 mg/day three times daily dosing | Prohibited except for acetaminophen, aspirin and anti-migraines | 8 weeks |
| Arnold et al., 2008 [24] | 41 704 | 50.1 ±11.4 | 300, 450 and 600 mg/day twice daily | Prohibited | 12 weeks |
| Mease et al., 2008 [23] | 42 706 | Placebo  Preg | 300 and 450 and 600 mg/day twice daily | Prohibited (except acetaminophen) | 12 weeks |
| Paure et al., 2011 [26] | 168 505 | Placebo  Preg 300  Preg 450  Preg 600 | 300, 450 and 600 mg/day twice daily | Not reported | 14 weeks |

*Preg – pregabalin*
Table IV. Summarized results for the studies with difference in mean pain score as outcome

| Pregabalin | Difference in mean ΔE (95% CI) | Cost of treatment (range – USD) | ICER (range) | The consideration based on comparison of ICER with threshold |
|------------|---------------------------------|---------------------------------|--------------|-----------------------------------------------------------|
| 150 mg/day [25] | *                               | (14–116)                        | NA           | NA                                                        |
| 300 mg/day [24] | –0.71 (–1.13, –0.29)             | (34–349)                        | 48 (30–117)  | 491 (309–1203)   | HCE  | HCE                                                      |
| 300 mg/day [25] | *                               | (23–233)                        | NA           | NA                                                        |
| 300 mg/day [23] | –0.43                            | (34–349)                        | 79           | 812                                                        | HCE  | HCE                                                      |
| 300 mg/day [26] | *                               | (34–349)                        | NA           | NA                                                        |
| 450 mg/day [24] | –0.98 (–1.40, –0.57)             | (62–550)                        | 63 (44–109)  | 561 (393–965)   | HCE  | HCE                                                      |
| 450 mg/day [25] | –0.93                            | (41–367)                        | 44           | 395                                                        | HCE  | HCE                                                      |
| 450 mg/day [23] | –0.47                            | (62–550)                        | 132          | 1170                                                       | HCE  | HCE                                                      |
| 450 mg/day [26] | –0.56                            | (62–550)                        | 111          | 982                                                        | HCE  | HCE                                                      |
| 600 mg/day [25] | –1.00 (–1.41, –0.59)             | (68–480)                        | 68 (48–115)  | 480 (340–814)   | HCE  | HCE                                                      |
| 600 mg/day [23] | –0.66                            | (68–480)                        | 103          | 727                                                        | HCE  | HCE                                                      |
| 600 mg/day [26] | *                               | (68–480)                        | NA           | NA                                                        |

*Non-significant results (95% CI), NA – not applicable, HCE – highly cost-effective

Table V. Summarized results for the studies with percentage of patients with more than 50% pain reduction as outcome

| Pregabalin | Difference in number of patients with 50% pain reduction (from 100 patients) ΔE |
|------------|---------------------------------------------------------------------------------|
| 300 mg/day [23] | 8 (3426–34943)                                                                 |
| 450 mg/day [23] | 8 (6166–55029)                                                                 |
| 600 mg/day [23] | 9 (6851–47961)                                                                 |

| Cost of treatment in 100 patients (range – USD) | ICER (range) | The consideration based on comparison of ICER with threshold |
|-----------------------------------------------|--------------|-----------------------------------------------------------|
| Generic                                      | Brand        |                                            |
| 428                                          | 4368         | HCE                                        |
| 771                                          | 6879         | HCE                                        |
| 761                                          | 5329         | HCE                                        |

CE – cost-effective, HCE – highly cost-effective

reported the efficacy of pregabalin 600 mg/day according to the outcome of percentage of patients with more than 50% pain reduction [23]. The ICER for generic and brand forms of this medicine based on this study was 761 and 5329, respectively (Table V). Considering these results from included studies, pregabalin 600 mg/day could be considered as highly cost-effective treatment for managing fibromyalgia in comparison to placebo.

Discussion

According to our analysis and based on available published evidence, pregabalin 150 mg/day is not a cost-effective treatment because of non-significant efficacy in comparison to placebo. However, the available evidence for this dose was not sufficient to make an appropriate decision. Concerning pregabalin 300 mg/day, there were some variations in the results of selected studies in terms of efficacy and cost-effectiveness. Three out of 5 studies indicated that pregabalin in this treatment dose is highly cost-effective, but in 2 studies no significant efficacy was found. Making a decision about this dose would depend on the view of policymakers and existence of further evidence. Pregabalin 450 mg/day according to the results of 3 out of 4 studies was highly cost-effective either with generic or brand forms. In addition, in one study, it was highly cost-effective in the generic form and cost-effective in the brand form. Pregabalin 600 mg/day in both generic and brand forms was highly cost-effective for fibromyalgia regardless of one study which showed no significant efficacy for this dose.

It is notable that this is the first cost-efficacy analysis in the context of Iran concerning use of pregabalin in fibromyalgia. Given that pregabalin is the only approved medicine for management of fibromyalgia and its availability in Iran in both generic and brand forms, this analysis can be useful for policymakers and also healthcare providers to make appropriate evidence-based decisions in their areas of activity.
Fibromyalgia is a disease which severely affects patients’ quality of life, especially in women [27]. A study comparing quality of life in women with fibromyalgia with some other pain-related illnesses such as osteoarthritis, rheumatoid arthritis, permanent osteotomies, chronic obstructive pulmonary disease, and insulin-dependent diabetes showed that the quality of life in patients with fibromyalgia is among the lowest in all attributes [28]. Another study indicated that patients with fibromyalgia suffer from difficulties in personal relationships, jobs and mental health [29], and experience anxiety [30]. A cost-effectiveness analysis in the context of the UK [31] using Markov modeling for 1 year to evaluate pregabalin in the treatment of fibromyalgia showed that the cost per quality-adjusted life year (QALY) gained for using pregabalin compared to placebo was £23,166 and £22,533 for doses of 300 mg/day and 450 mg/day, respectively. They concluded that pregabalin is a cost-effective treatment. In another study in the US [32], a cost-effectiveness analysis was conducted to compare different fibromyalgia management strategies by a decision-analytic model and indirect effectiveness comparison. The results indicated that pregabalin is cost-saving and more effective than placebo, duloxetine, tramadol, milnacipran, and gabapentin.

In our study, we did not use any decision tree or Markov model for economic evaluation of pregabalin in the treatment of fibromyalgia. In estimation of costs related to this treatment, only direct medical costs were taken into account and direct non-medical or indirect costs were excluded. Including these items, we can claim that pregabalin is a more cost-effective treatment.

Considering the present results, pregabalin 450 mg/day and 600 mg/day are recommended to be included in clinical practice guidelines and reimbursement schemes, given that there is no other FDA approved alternative available in the Iranian market. More accurate decisions about pregabalin 300 mg/day need further evidence. Although pregabalin was cost-effective in both generic and brand forms, considering the bioequivalent efficacy of brand and generic forms, including pregabalin in the reimbursement positive list in the generic form would be more rational and cost-saving. Also more direct evidence regarding comparison of pregabalin and other approved medicines including duloxetine and milnacipran is needed to make the decision in a more efficient way.

In conclusion, based on the published available evidence and cost of pregabalin in Iran, pregabalin 450 mg/day and 600 mg/day can be recommended as a cost-effective treatment for fibromyalgia and can be included in clinical practice guidelines and insurance positive lists of Iran. The decision about pregabalin 300 mg/day is dependent on the viewpoint of policymakers and future evidence. A final point is that more evidence on comparison of pregabalin and other approved or off-label alternatives in head-to-head trials is needed to make a more efficient, convincing decision.

Acknowledgments

The authors would like to appreciate the National Health Research Institute and Health Technology Assessment Department of the Iranian Ministry of Health and Medical Education for financial support of this study in part and also Dr Shekoufeh Alaei for her valuable consultation.

References

1. Russell IJ, Raphael KG. Fibromyalgia syndrome: presentation, diagnosis, differential diagnosis, and vulnerability. CNS Spectr 2008; 13: 6-11.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
3. Branco JC, Bannwarth B, Faille I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2009; 39: 448-53.
4. Forzanizade J, Abhari R, Shakibi MR, Pirozam M, Samaﬁ, D, Tavakoli-Bazaz S. Prevalence of rheumatoid in Tehran. J Iran Univ Med Sci 1995; 3: 182-91.
5. Naji A, Arab F. Prevalence of fibromyalgia syndrome in patients referring to Shariati hospital, Tehran. Tehran Univ Med J 2007; 64: 60-6.
6. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160-72.
7. Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006; 8: 212.
8. Merchant RE, Andre CA. A review of recent clinical trials of the nutritional supplement Chlorella pyrenoidosa in the treatment of fibromyalgia, hypertension, and ulcerative colitis. Altern Ther Health Med 2001; 7: 79-91.
9. US Food and Drug Administration. FDA Approves First Drug for Treating Fibromyalgia. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01656.html.
10. FDA Center for Drug Evaluation and Research. Approval duloxetine (Cymbalta). June 13, 2008. Available from: http://www.fda.gov/cder/foi/appletter/2008/022148s000ltr.pdf.
11. FDA Center for Drug Evaluation and Research. Approval milnacipran (Savella). January 13, 2009. Available from: http://www.fda.gov/cder/foi/appletter/2009/022256s000ltr.pdf.
12. Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004; 31: 1391-8.
13. Annemans L, Le Lay K, Charles T. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics 2009; 27: 547-59.
14. AbdollahiaslA, Nikfar S, Kebrayeazadeh A, Dinavand R, Abbodlahi M. A model for developing a decision support system to simulate national drug policy indicators. Arch Med Sci 2011; 7: 744-6.
15. Nikfar S, Kebrayeazadeh A, Majdzadeh R, Abdollahi M. Monitoring of national drug policy (NDP) and its standardized indicators; conformity to decisions of the
A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience

16. Cheraghali AM, Nikfar S, Behmanesh Y, et al. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. East Mediterr Health J 2004; 10: 406-15.
17. Nikfar S, Khatibi M, Abdollahiasl A, Abdollahi M. Cost and utilization study of antidotes: an Iranian experience. Int J Pharmacol 2011; 7: 46-9.
18. Hashemi Meshkini A, Keshvarz K, Gharinasseri Z, Nikfar S, Abdollahi M. The cost-effectiveness of pregabalin in the treatment of diabetic peripheral neuropathy: a systematic review and economic model. Int J Pharmacol 2012; 8: 490-5.
19. Nikfar S. A new model for decision analysis in economic evaluations of switchable health interventions. J Med Hypotheses Ideas 2012; 6: 12-5.
20. Jadad A. Randomized controlled trials. BMI Books, London 1998.
21. World Health Organization, 2012. Choosing interventions that are cost effective (WHO-CHOICE).
22. World Economic Outlook Database, April 2012. International Monetary Fund. Accessed from http://www.imf.org/external/pubs/ft/weo/2012/01/weodata/index.aspx.
23. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase iii trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008; 35: 502-14.
24. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008; 9: 792-805.
25. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-73.
26. Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of Pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011; 38: 2643-52.
27. Roshan R, Shariatpanahi SS, Tavoli A, Qafori Z, Fathi-Ashtiani A. Quality of life in women with fibromyalgia. Arch Med Sci 2009; 5: 267-70.
28. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993; 20: 475-9.
29. Bernald AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res 2000; 13: 42-50.
30. Pagano T, Matsutani LA, Ferreira EA, Marques AP, Pereira CA. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J 2004; 122: 252-8.
31. Choy E, Richards S, Bowrin K, et al. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin 2010; 26: 965-75.
32. Lloyd A, Boornishine CS, Choy EH, Chandran A, Zlateva G. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J Med Econ 2012; 15: 481-92.